Knight Therapeuticsの株式の価格
Knight Therapeuticsの株式の価格 は何ですか。
Knight Therapeutics, Inc.の株式の価格 は1.54です。
株式の価格 の定義は何ですか。
1株当たりキャッシュは、会社の手持ち現金を会社の発行済株式で割ったものです。
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
TSXのセクタHealth Careにおける株式の価格 の企業と比べるKnight Therapeutics
Knight Therapeuticsは何をしますか。
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Knight Therapeuticsと類似の株式の価格
- Nuvasive Incの株式の価格 は1.54です。
- Central Bank of Indiaの株式の価格 は1.54です。
- Umicoreの株式の価格 は1.54です。
- TSSの株式の価格 は1.54です。
- Shenzhen Chipscreen Biosciences Coの株式の価格 は1.54です。
- Allied Properties (H.K.)の株式の価格 は1.54です。
- Knight Therapeuticsの株式の価格 は1.54です。
- Tyson Foodsの株式の価格 は1.54です。
- Gen Digital Incの株式の価格 は1.54です。
- Aviat Networks Incの株式の価格 は1.54です。
- Detection Technology Oyjの株式の価格 は1.54です。
- Simmonds Marshallの株式の価格 は1.54です。
- Service Internationalの株式の価格 は1.54です。